Navigation Links
Case Western Reserve receives $1.6M to study tumor cells and immune cell detection

Case Western Reserve University School of Medicine has received a $1.6 million grant from the National Cancer Institute (NCI) to study how tumor cells avoid detection by the body's immune system, allowing cancer to develop and spread.

The five-year National Institutes of Health grant will enable researchers led by Alex Y. Huang, MD, PhD, assistant professor of pediatrics, pathology, and biomedical engineering at the School of Medicine, and a hematologist and oncologist at Rainbow Babies & Children's Hospital at University Hospitals Case Medical Center, to examine "immune tolerance." The process keeps tumor cells from being detected by the immune system, even when they invade draining lymph nodes, a place where primary immune activation and surveillance take place. Lymph nodes are part of the body's lymphatic system, which fights off viruses, bacteria, and other disease-causing agents.

The study will also test whether modifying the environment in which tumor and immune cell interactions take place, using a group of proteins called inflammatory chemokines, will activate unresponsive immune cells into fighting off cancer. Using inflammatory chemokines as part of the anti-tumor strategies is a novel approach to cancer treatment.

"This research will provide greater insight into the potential therapeutic utilities of inflammatory chemokines, thereby providing a new direction for the development of immunotherapies that are capable of fighting cancer at the most basic cellular level," Dr. Huang says, who is also an associate member of the Case Comprehensive Cancer Center at the School of Medicine and director of the Pediatric Hematology-Oncology Fellowship Program at Rainbow Babies & Children's Hospital. "Any effective cellular immunotherapy must enhance long-term tumor immunity, effectively concentrating immune cells and priming them to destroy cancer cells anywhere in the body over long periods of time."

Researchers will work to leverage the immune system's unique ability to generate immune memory to eradicate any future cancer cell development that is derived from a primary tumor, according to Dr. Huang. They will use an advanced imaging technique called intravital 2-photon laser scanning microscopy to directly visualize tumor and immune cell interactions in real-time.

Dr. Huang's laboratory has been at the forefront of developing this imaging technology, which he says provides a "court-side" view of how tumors and the immune system interact with one another within intact tissue as cancer spreads to the lymph nodes. The technology is designed to provide a powerful in vivo experimental platform to monitor future anti-cancer or immunotherapy approaches, as opposed to static tissue analysis or single-cell analysis on a plastic petri dish, he explains.

Dr. Huang's research is among the first attempts to directly visualize the tolerance of immune cells by metastatic cancer cells in the draining lymph node at a cellar level, in a dynamic fashion.

As a practicing pediatric hematologist and oncologist, Dr. Huang aims to one day be able to apply the scientific insight gained from this research in a pediatric care setting.


Contact: Jessica Studeny
Case Western Reserve University

Related medicine news :

1. UT Southwestern research advances fight against kidney cancer
2. Annual sonograms are needed to verify correct IUD position, UT Southwestern obstetricians say
3. Northwestern Medicine multiple sclerosis program earns national designation
4. UT Southwestern receives $36.7 million for cancer research
5. Foster parents receive more support than kinship caregivers, UT Southwestern study finds
6. UT Southwestern launches clinical trial for treatment of breast cancer using CyberKnife
7. Homogeneous tuberculosis treatment ineffective in children, UT Southwestern researchers find
8. Western Diet May Raise Risk of Kidney Function Decline
9. Helping others helps alcoholics stay on the road to recovery, Case Western Reserve shows
10. Case Western Reserve receives $7.8M to study manic symptoms in children
11. Case Western Reserve and Athersys show regenerative benefit of MultiStem after spinal cord injury
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: